🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

449 results for “Sun” Clear

  1. Midazolam-ratiopharm® 2 mg/ml orale Lösung, JNJ-42756493, JNJ-42756493, Metformin HEXAL 1000 mg Filmtabletten, JNJ-42756493

    Janssen-Cilag International N.V.

    Urothelial cancer

    phase 2 small molecule active

    1 trial

  2. Mosunetuzumab

    Adaptive Biotechnologies Corp

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  3. Mosunetuzumab

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  4. Mosunetuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  5. Mosunetuzumab, Mosunetuzumab, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Mosunetuzumab, Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  6. Mosunetuzumab, Mosunetuzumab, TOCILIZUMAB , BRUKINSA 80 mg hard capsules

    Fondazione Telethon ETS

    Follicular lymphoma

    phase 2 small molecule active

    1 trial

  7. Niraparib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Platinum-resistant Recurrent Clear Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  8. Online adaptive SBRT

    Sun Yat-sen University

    Adaptive Radiotherapy

    phase 2 other active

    1 trial

  9. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  11. Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, 5-FU medac 50 mg/ml, Injektionslösung, DS-8201a

    The George Institute

    HER2 positive resectable esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. PARACETAMOL , FEXOFENADINE , CETIRIZINE , DEXAMETHASONE , mRNA-3745, DIPHENHYDRAMINE , CARBOHYDRATES , IBUPROFEN , HYDROXYZINE , FAMOTIDINE , Isotonische Kochsalzlösung Fresenius, Infusionslösung, ONDANSETRON

    Moderna Biotech Spain

    Glycogen storage disease type 1a (GSD1a)

    phase 2 small molecule active

    1 trial

  13. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia and other blood cancers

    phase 2 small molecule active

    1 trial

  14. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  15. Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé

    Partner Therapeutics Limited

    ER-positive/HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  16. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  17. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Boehringer Ingelheim

    locally advanced or metastatic NSCLC

    phase 2 small molecule active

    1 trial

  18. Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion, REGN7075, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., LIBTAYO 350 mg concentrate for solution for infusion., Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml Infusionslösung, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslös

    Gilead Sciences Pty Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. Polivy 30 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  21. Pregabalin

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  22. Probiotics Compound (Biolosion)

    Sun Yat-sen University

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  23. Pucotenlimab

    Sun Yat-sen University

    Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  24. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources